Anti-DARPP-32

Dopamine and cAMP-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32) is a member of the protein phosphatase inhibitor 1 family and is encoded by the PPP1R1B gene in humans. It is primarily expressed in medium spiny neurons of dopamine-innervated brain regions and is localized to the cytoplasm. DARPP-32 contains multiple phosphorylation sites that allow it to function as a central regulator and integrator of signaling cascades induced by a variety of neurotransmitters, neuropeptides, and psychostimulatory agents. It also contains a protein phosphatase 1 (PP1) binding domain. DARPP-32 inhibits PP1 when phosphorylated at threonine 34 (Thr34) by PKA and inhibits PKA when phosphorylated at Thr75 by cyclin-dependent kinase 5 (Cdk5). Ppp1r1b-/- mice have decreased amphetamine-induced GABA and dopamine release in the striatum and are less susceptible to catalepsy induced by raclopride (Cay-17422) compared to wild-type mice. Increased DARPP-32 protein levels have been identified in breast, prostate, gastric, and colon cancer tumors. DARPP-32 levels are also increased in postmortem-derived dorsolateral prefrontal cortex from individuals with schizophrenia or bipolar disorder. Cayman's DARPP-32 Polyclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications. The antibody recognizes DARPP-32 at ~32 kDa from mouse and rat samples.Synonyms: Protein Phosphatase 1 Regulatory Subunit 1B. Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of rat DARPP-32 conjugated to KLH. Formulation: (Request formulation change), 100 µl of polyclonal antibody prepared from pooled rabbit serum via chromatography on an affinity column prepared with the N-terminal peptide used as antigen. Storage Buffer: 10 mM HEPES, pH 7.5, with 150 mM sodium chloride, 100 µg/ml BSA, and 50% glycerol. Host: Rabbit. Applications: IHC, WB.